Observation of the Curative Effect of the Dexamethasone Vitreous Cavity Implant for the Treatment of Irvine-Gass Syndrome

Objective To investigate the clinical efficacy of dexamethasone vitreous cavity implants (Ozurdex) for the treatment of macular edema (Irvine-Gass Syndrome) after cataract surgery. Method Eight patients (eight eyes) with Irvine-Gass syndrome were enrolled for vitreous injections with Ozurdex. The patients included six men (six eyes) and two women (two eyes) with a mean age of 67.12 +/- 11.92 years. Changes in the patients best-corrected visual acuity (BCVA), central macular thickness (CMT), and intraocular pressure were compared before and after treatment. Result The mean visual acuity BCVA of the patients was 0.81 +/- 0.26 before implantation, which improved to 0.20 +/- 0.12, 0.13 +/- 0.09, and 0.15 +/- 0.13 at 2 weeks, 1 month, and 3 months after implantation, respectively (P < 0.001). The patient's mean CMT before implantation was 703.00 +/- 148.88 mu m, and it reduced to 258.87 +/- 37.40 mu m, 236.25 +/- 28.74 mu m, and 278.00 +/- 76.82 mu m at 2 weeks, 1 month, and 3 months after implantation, respectively (P < 0.001). Conclusion The dexamethasone vitreous cavity implant (Ozurdex) is a safe and effective treatment, which can effectively improve patient's visual acuity and reduce macular edema associated with cataract surgery.